Browse by author
Lookup NU author(s): Dr Shannon Jamieson, Amy Mawdesley, Dr Philip Hyde, Emeritus Professor John Kirby, Professor Alison Tyson-Capper
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Total hip replacement (THR) is indicated for patients with osteoarthritis where conservative treatment has failed. Metal alloys used in THR implants such as cobalt-chromium (CoCr) have been known to cause pro-inflammatory reactions in patients, therefore leading to the need for costly revision surgery. This study therefore aimed to investigate the role of TLR4 in the activation of a human osteoblast model in response to CoCr particles in vitro.Human osteoblasts (MG-63 cell line) were seeded at a density of 100,000 cells and treated with 0.5, 5, 50mm3 CoCr particles per cell for 24-hours. Trypan blue and the XTT Cell Proliferation Kit II were then used in conjunction with the cells to assess CoCr-induced cytotoxicity. Cells were pre-treated with a commercially available TLR4-specific small molecule inhibitor (CLI-095) for 6 hours. Untreated cells were used as a negative control and lipopolysaccharide (LPS) was used as a positive control. Following treatment the cell supernatant was collected and used for enzyme-linked immunosorbant assay (ELISA) to measure the secretion of interleukin-8 (IL-8), CXCL10, and interleukin-6 (IL-6).Trypan blue and XTT analysis showed that there was no significant changes to cell viability or proliferation at any dose used of CoCr after 24 hours. There was a significant increase in protein secretion of IL-8 (p<0.001), CXCL10 (p<0.001), and IL-6 (p<0.001) in the cells which received the highest dosage of CoCr. This pro-inflammatory secretory response was ameliorated by TLR4 blockade (p<0.001).CoCr particles are not cytotoxic to osteoblasts but they do induce pro-inflammatory changes as characterised by increased secretion of chemokines IL-8, CXCL10, and IL-6. These responses occur via a TLR4-mediated pathway and upon inhibition they can be effectively ameliorated. This is particularly important as TLR4 could be a potential target for pharmacological intervention used in patients experiencing immunological reactions to metal implant debris.
Author(s): Jamieson S, Mawdesley A, Hyde P, Kirby J, Tyson-Capper A
Publication type: Conference Proceedings (inc. Abstract)
Publication status: Published
Conference Name: The International Combined Orthopaedic Research Societies (ICORS), World Congress of Orthopaedic Research
Year of Conference: 2022
Pages: 6-6
Print publication date: 04/04/2023
Online publication date: 04/04/2023
Acceptance date: 02/04/2018
ISSN: 2049-4416
Publisher: British Editorial Society of Bone and Joint Surgery
URL: https://doi.org/10.1302/1358-992X.2023.7.006
DOI: 10.1302/1358-992X.2023.7.006
Series Title: Orthopaedic Proceedings
